IL-17 Neutrophils in CF Lung Inflammation

Inclusion Criteria

• •For Both Cohorts: ≥ 18 \< 50 years of age
• •For Both Cohorts: Must have a documented diagnosis of CF (positive sweat chloride ≥60 milliequivalents (mEq)/liter, by pilocarpine iontophoresis) and/or a genotype with two identifiable mutations consistent with CF accompanied by one or more clinical features with the CF) phenotype
• •For Both Cohorts: Chronically infected with P. aeruginosa defined by 2 positive cultures in the past year or 3 in the last two years
• •For Both Cohorts: Ability to expectorate mucus
• •For Both Cohorts: Ability to provide written informed consent
• •For Clinically Stable Cohort: 4 subjects with one copy of G551D
• •For Clinically Stable Cohort: 10 subjects who do not have G551D, they must have one copy of F508del
• •For Clinically Stable Cohort: CF subjects must have a baseline FEV1 percent predicted \> 50% (in the last year, obtained from medical record)
• •For Clinically Stable Cohort: Clinically stable: free of any acute illness for \>14 days
• •For Clinically Stable Cohort: Must have performed spirometry for clinical purposes at that clinical visit
• •For Clinically Stable Cohort: Must have a sputum culture sent to the clinical lab for clinical purposes at the time of the study visit
• •For Clinically Stable Cohort: Have not been prescribed any new systemic antibiotics for the 14 days prior to enrollment
• •For Exacerbation/IV Antibiotics Cohort: One copy of F508del
• •For Exacerbation/IV Antibiotics Cohort: Must have a doctor defined pulmonary exacerbation requiring treatment with IV antibiotics
• •For Exacerbation/IV Antibiotics Cohort: Must have performed spirometry for clinical purposes within 72 hours of initiating IV antibiotics and within 72 hours of completing IV antibiotics
• •For Exacerbation/IV Antibiotics Cohort: Must have a sputum culture sent to the clinical lab for clinical purposes within 72 hours of admission